BriaCell Therapeutics Announces Pricing of Offering
Rhea-AI Summary
BriaCell Therapeutics (Nasdaq:BCTX) priced a best-efforts offering of 1,449,300 common shares at $3.25 per share, for expected gross proceeds of about $4.7 million before fees. Closing is expected on June 2, 2026, subject to customary conditions.
Net proceeds are intended for working capital, general corporate purposes, and advancing business objectives. ThinkEquity is sole placement agent. The offering uses BriaCell’s effective Form S-3 shelf registration.
Positive
- Equity financing expected to raise approximately $4.7 million gross
- Proceeds allocated to working capital and business advancement
- Offering conducted under an already effective Form S-3 shelf
- Best-efforts offering fully comprised of primary shares by the company
Negative
- New common share issuance implies equity dilution for existing holders
- Best-efforts structure provides no firm commitment to place all shares
- Gross proceeds are before placement fees and offering expenses, reducing net cash received
News Market Reaction – BCTX
In the Jun 1 session, BCTX declined 9.07%, reflecting a notable negative market reaction. Argus tracked a trough of -5.2% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 16 | Offering closing | Negative | +1.1% | Closed $15M unit offering with warrants at $1.25 per unit. |
| Jul 15 | Offering pricing | Negative | -61.8% | Priced $15M public offering of 12M units with warrants. |
| Apr 28 | Offering closing | Negative | -8.2% | Closed $13.8M unit offering at $4.50 with $5.25 warrants. |
| Apr 24 | Offering pricing | Negative | -13.8% | Priced $13.8M public unit offering at $4.50 with warrants. |
| Feb 05 | Offering closing | Negative | -9.6% | Closed best-efforts offering of 762,500 shares for $3.05M. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past financing announcements have usually been followed by negative price moves, with only one modestly positive reaction out of five offering-related events.
Over the past year, BriaCell repeatedly tapped the equity markets, including public offerings on Feb 5, 2025, Apr 24 & 28, 2025, and Jul 15 & 16, 2025. These financings raised between $3.05M and $15M, often via unit structures including warrants, and most carried immediate share price declines. Today’s offering continues this pattern of funding late-stage oncology programs through equity issuance, following substantial R&D investment and prior going‑concern disclosures.
Key Terms
best-efforts offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of
The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.
ThinkEquity is acting as sole placement agent for the offering.
The securities described above are being offered and sold by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-276650), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 22, 2024 and declared effective on January 31, 2024. The offering is being made only by means of a written prospectus. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and can be accessed for free on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.
Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
